CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Rosemary Harrison Joins TCR Therapeutics as Chief Business and Strategy Officer

Rosemary Harrison Joins TCR...

Clinical Research Technology Leader RealTime Secures Growth Investment from LLR Partners

Clinical Research Technology Leader...

Catalyst Biosciences Announces Major Leadership Changes

Catalyst Biosciences Announces Major...

Merakris Therapeutics Partners with Miracles In Sight Eye Bank

Merakris Therapeutics Partners with...

BetterLife- Carleton University Research Team Secures Funding form Mitacs

BetterLife- Carleton University...

ClearPoint Neuro Appoints Lynnette C. Fallon to Board of Directors

ClearPoint Neuro Appoints Lynnette C....

Marc Drimer, CPA, Joins the Board of Directors of Curative Biotechnology

Marc Drimer, CPA, Joins the Board of...

James Pekarsky Joins Gelteq as Chief Financial Officer

James Pekarsky Joins Gelteq as Chief...

Rosemary Harrison Joins TCR Therapeutics as Chief Business and Strategy Officer

Rosemary Harrison Joins TCR...

Clinical Research Technology Leader RealTime Secures Growth Investment from LLR Partners

Clinical Research Technology Leader...

Catalyst Biosciences Announces Major Leadership Changes

Catalyst Biosciences Announces Major...

Merakris Therapeutics Partners with Miracles In Sight Eye Bank

Merakris Therapeutics Partners with...

BetterLife- Carleton University Research Team Secures Funding form Mitacs

BetterLife- Carleton University...

ClearPoint Neuro Appoints Lynnette C. Fallon to Board of Directors

ClearPoint Neuro Appoints Lynnette C....

Marc Drimer, CPA, Joins the Board of Directors of Curative Biotechnology

Marc Drimer, CPA, Joins the Board of...

James Pekarsky Joins Gelteq as Chief Financial Officer

James Pekarsky Joins Gelteq as Chief...

Biosplice Therapeutics Raises $ 120 M in Equity Funding

Life Sciences Review Life Sciences Review | Wednesday, April 28, 2021
Tweet

Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management, and others are among the investors in this latest round, which also includes established investor support.


FREMONT, CA: Biosplice Therapeutics (Biosplice), a clinical-stage biotechnology company that is developing therapeutics for major diseases based on alternative pre-mRNA splicing, announced that it has raised 120 million dollars in equity funding from a new biotechnology investment syndicate. Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management, and others are among the investors in this latest round, which also includes established investor support. Joy Ghosh, Ph.D., of Eventide Asset Management, and Gur Roshwalb, MD, of aMoon will join the company’s Board of Directors as part of the financing.


“We are delighted to align with our new investors and board behind the immense therapeutic potential of Biosplice,” said CevdetSamikoglu, Chief Executive Officer of Biosplice. “This investment round positions us to accelerate the development and launch of lorecivivint, our groundbreaking Phase 3 program in osteoarthritis. In addition, we expect to realize the tremendous potential of our oncology program, as well as neurology and other areas of significant unmet need.”


Biosplice is designing small-molecule therapeutics that are first-in-class, based on the cutting-edge technology of alternative pre-mRNA splicing. Biosplice has elucidated novel biology connecting CLK/DYRK kinases to the therapeutic control of alternative splicing, based on foundational discoveries in Wnt pathway modulation. Alternative splicing is a crucial biological process that controls the diversity of proteins in a cell, which determines the cell’s form and function. Within the cellular command and control center, the Biosplices target class controls the selection of tissue-specific mRNA splice sites, rendering them attractive, druggable targets.


Joy Ghosh, Ph.D., of Eventide Asset Management, added, “Biosplices alternative splicing platform has enormous potential to address critical needs in osteoarthritis, oncology and neurology, among others. We are particularly excited by lorecivivint, which has the potential to be a first-in-class medicine that could confer both symptomatic and disease-modifying benefits to hundreds of millions of osteoarthritis sufferers worldwide.”


Weekly Brief

loading
> <
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue

Read Also

Everything You Need to Know About Medical Lab Equipment and their Applications

Everything You Need to Know About Medical Lab Equipment and their Applications

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural Genome Editing
Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks To Buy In 2022

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/biosplice-therapeutics-raises-120-m-in-equity-funding-nwid-342.html